No headlines found.
Business Wire (Thu, 21-Mar 7:45 AM ET)
Business Wire (Wed, 20-Mar 4:30 PM ET)
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
Business Wire (Mon, 18-Mar 4:05 PM ET)
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
Business Wire (Thu, 7-Mar 4:30 PM ET)
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
Business Wire (Mon, 26-Feb 4:30 PM ET)
Alpine Immune Sciences Inc is a clinical-stage biopharmaceutical company dedicated to discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. Its approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its pipeline candidates are; ALPN-303, or povetacicept, is a dual antagonist of the B cell activating factor, or BAFF, and a proliferation-inducing ligand, or APRIL, cytokines, which play key roles in the activation, development, and survival of B cells, and ALPN-101, or acazicolcept, is a dual Inducible T cell Costimulator, or ICOS, and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.
Alpine Immune Sciences trades on the NASDAQ stock market under the symbol ALPN.
As of March 28, 2024, ALPN stock price climbed to $40.27 with 799,129 million shares trading.
ALPN has a beta of 3.37, meaning it tends to be more sensitive to market movements. ALPN has a correlation of 0.23 to the broad based SPY ETF.
ALPN has a market cap of $2.64 billion. This is considered a Mid Cap stock.
Last quarter Alpine Immune Sciences reported $31 million in Revenue and $.15 earnings per share. This beat revenue expectation by $22 million and exceeded earnings estimates by $.49.
In the last 3 years, ALPN stock traded as high as $42.88 and as low as $4.82.
The top ETF exchange traded funds that ALPN belongs to (by Net Assets): XBI, VTI, IWM, VXF, IBB.
ALPN has outperformed the market in the last year with a price return of +475.3% while the SPY ETF gained +33.9%. ALPN has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +102.2% and +10.0%, respectively, while the SPY returned +10.3% and +1.9%, respectively.
ALPN support price is $37.36 and resistance is $39.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALPN stock will trade within this expected range on the day.